Idenix (IDIX) Said SEBIVO Demonstrated Better Antiviral Activity Compared to Adefovir

April 13, 2007 12:51 PM EDT

Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) said, in a comparative study, SEBIVO provided more rapid and profound viral suppression than adefovir both in newly diagnosed HBeAg-positive patients and in those who switched from adefovir to SEBIVO.

Additionally, regardless of treatment, a substantial early reduction in virus level correlated with better outcomes such as maintained undetectable levels of virus (PCR-negativity), HbeAg seroconversion and ALT normalization, at one year. A significantly greater percentage of SEBIVO patients achieved PCR-
negativity (38 percent; n=17/45) compared to adefovir-treated patients (12 percent; n=11/90) by six months. These findings were presented at the Annual Meeting of the European Association for the Study of the Liver.

Idenix and Novartis Pharma AG are co-promoting SEBIVO (telbivudine), for the treatment of hepatitis B, and co-developing valtorcitabine, a second hepatitis B compound, and valopicitabine, a hepatitis C compound, under a development and commercialization arrangement established in May 2003.

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?